We are excited to announce that Lisa Mahnke, MD, PhD, CEO/President, Nerviano Medical Sciences, Inc; CMO, Nerviano Medical Sciences, Srl, will participate as a Guest Speaker at the 8th Annual DDR Inhibitors Summit taking place in Boston from January 28-30.
Lisa’s presentation Exploring Next-Gen PARP Inhibitors without PARP Trapping, scheduled for January 30th at 3:45 PM, will focus on:
- Evaluating next-gen PARP inhibitors that selectively target PARP1 without trapping, aiming to minimize hematological toxicity and enhance safety in combination with DNA-damaging agents
- Focusing on improving blood-brain barrier penetration to address the unmet needs in treating brain metastases and glioblastomas
- Exploring the potential of these next-gen PARP inhibitors in combination with various DNA-damaging therapies to broaden their therapeutic applications
The DDR summit serves as a key gathering for biopharma drug developers and researchers to collaborate on advancing DDR therapeutics. Over 100 experts from discovery, preclinical, translational, regulatory, and clinical fields will come together to explore the potential of DDR inhibitors in cancer treatment and improve patient outcomes.
